> 'India should walk on her own shadow- we must have our own development model'
>
> -APJ Abdul Kalam

Hypertension is a major global public health problem. It affects 1.13 billion individuals and accounts for 45 per cent of all heart disease related deaths and 50 per cent of all stroke related deaths worldwide[@ref1]. India with a population of 1.32 billion contributes a large part of this burden. While we need to think globally, we shall have to act locally and nationally since some issues with hypertension are different in our country due to our unique genetic, social, economic, dietary and other lifestyle factors.

Hypertension in India has some special features such as onset occurs relatively early in life, a rural-urban divide, the prevalence in urban areas is 33.8 per cent and in rural areas, it is 27.6 per cent with an overall prevalence of 29.8 per cent[@ref2]. There is a clustering of multiple cardiovascular risk factors in Indians, and there is also a significant seasonal variation of blood pressure (BP). The average BP in general population has been rising in the last two decades as against a decrease seen in some western countries[@ref2]. Furthermore, the awareness of hypertension is 42 per cent in urban and 25 per cent in rural individuals. The treatment is taken by 38 per cent urbans and 25 per cent rurals[@ref2]. Only 20 per cent of urbans and 11 per cent of rurals have control of BP[@ref2]. This is much less than the figures in other nations like in the US where awareness, treatment and control are 81, 74 and 53 per cent, respectively[@ref3].

The health care delivery system in our country is also different as we spend four per cent of our gross domestic product on health which is half of the world average[@ref4]. Only 25 per cent of Indians have some form of insurance, and 80 per cent of outpatient department visits are taken care by the private sector[@ref4]. For all these reasons, we will have to find our own ingenious and indigenous solutions to this huge problem according to our circumstances.

Going by the simple theme of World Hypertension Day 'Know your numbers' there are two issues which have come up more recently especially for us in India that complicate the attempted simplification of this core message. The sooner we clarify these, the easier and faster will our efforts to control this highly prevalent 'risk factor-disease' become.

The first is regarding the apparatus to be used to know the numbers. The simple measuring device that we used for a century is now in a state of uncertainty[@ref5]. The mercury sphygmomanometer has been phased out from most parts of the world. The WHO has taken it as a mission to phase out mercury apparatus by 2025[@ref6]. This is required and has to be done to prevent the cumulative toxic effects of mercury. There is a need to develop uniform, reliable, accurate and reproducible method for measurement of BP. We do recognize that we need to shift to aneroid and oscillometric digital BP measuring devices. However, both these devices require periodic calibrations which were required less often with mercury. We also do not have any BP calibration laboratories across the country, and so it all depends on individual users and physicians to check its reproducibility and reliability. There are no guidelines for BP apparatus manufacturers and their accreditation. A system needs to be developed in India as is existent in Europe, Britain and America. In fact, for the sake of uniformity US Association for the Advancement of Medical Instrumentation, the British Hypertension Society, the European Society of Hypertension have collectively formed a group for giving guidelines regarding instrument manufacturing and standardization[@ref7].

The latest Canadian guidelines advocate the use of automated office BP (AOBP) for diagnosis of hypertension[@ref8]. The SPRINT (Systolic Blood Pressure Intervention Trial) study[@ref9] also used this method, and the latest American College of Cardiology/American Heart Association (ACC/AHA) guidelines on hypertension[@ref10] are based on data from trials with these instruments. These instruments are much more expensive, none is being manufactured in India and are less likely to be widely used here. Thus, we need to develop methodologies and systems for the standard of equipment manufactured and available for a physician in our country.

The second issue that has cropped up is, once we 'know the numbers' what significance do we attach to these. The very definition of hypertension which for the last 30 years was globally accepted as 140/90 mmHg has been challenged by the ACC/AHA guidelines released last year[@ref10]. No other recent national guidelines (Canadian 2017[@ref8] and Australian 2016[@ref11]) have changed the definition to 130/80 mmHg which is the new definition by the ACC/AHA guidelines[@ref10]. In India, we already have two Indian guidelines, the more popular Indian Guidelines on Hypertension (IGH) III-2013 (third in a series, 2001 and 2007 were the first and second) which have been jointly drafted and accepted by the Association of Physicians of India (API) and Hypertension Society of India (HSI) and endorsed by the Cardiological Society of India and Indian Medical Association[@ref12]. The other Indian guidelines are the more recent 'Standard Treatment Guidelines' released by the Ministry of Health and Family Welfare in May 2016[@ref13]. These guidelines have come up after the SPRINT study but have retained the definition of hypertension as 140/90 mmHg and graded it I, II and III with increments of 20 mm in systolic and 10 mm in diastolic BP. This grading is same as in the IGH-III by API/HSI.

The SPRINT study is the basis for this reclassification and new targets by the ACC/AHA. We have no idea what will be the conversion factor for physician recorded office BP (PROBP) which is done in India to the AOBP recording (which was used in the SPRINT). Some experts feel it could be 10-15 mmHg higher for the PROBP[@ref14]. This brings us closer to the existing targets. Greater control will mean larger number of drugs and consequently increased cost and frequent investigations to look at side effects. Our emphasis here should be to include greater number of individuals with hypertension in terms of its awareness and subsequent control as a nation since that will impact morbidity and mortality to a larger extent. The Indian experts would prefer a target of 135/85 mmHg as used by Canadians[@ref8].

The new ACC/AHA guidelines[@ref10] will, however, impact care in our region also, for the following reasons: First, since these have drawn the attention of policymakers, physicians and the general public that good control of BP means reduced mortality. Second, a common notion for a long time that was further supplemented by the 8^th^ Joint National Committee (JNC 8)[@ref15], that in elderly we should accept higher targets will now be changed, and hopefully, elderly (\>75 yr) who derive even greater benefits will have better control. The SPRINT study and ACC/AHA guidelines used 10 years atherosclerotic cardiovascular disease (ASCVD) risk calculator which has not been validated for Indian population[@ref9][@ref10]. Thus, in India we need to develop our own risk calculation scoring system. A comparison of the ACC/AHA guidelines and the two Indian guidelines is shown in [Table](#T1){ref-type="table"}.

###### 
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A general practitioner who manages most patients of hypertension may be confused regarding the best, safe and most reliable instrument to be used today as also the definition and targets for BP control. We need to take steps in this direction in a collective form, develop BP apparatus manufacturing and validation guidelines and facilities that are widely available, cost-effective and can be used by single physician and public/private hospitals both. At the same time, we should put emphasis on better control, involvement of patients in the treatment process, greater use of home BP recordings and an 'individualized care approach' to the management of hypertensive patients aimed at 'overall risk reduction' and consequently target organ effects. We should be moving to an individualized care in which the patient profile (race, age, risk factors, associated diseases & target organ damage) and the BP value will both have an equal effect on choice and need for antihypertensive medications and the targets to be achieved. Let us also untangle some of these knots and project the evidence base in a simplistic manner that can be translated into practice regarding definitions and targets of BP for our country by forming collective guidelines.
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[^1]: This editorial is published on the occasion of World Hypertension Day - May 17, 2018.
